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Controlling cell proliferation is one of the hallmarks of cancer. A number of critical
checkpoints ascertain progression through the different stages of the cell cycle, which
can be aborted when perturbed, for instance by errors in DNA replication and repair.
These molecular checkpoints are regulated by a number of proteins that need to be
present at the right time and quantity. The ubiquitin system has emerged as a central
player controlling the fate and function of such molecules such as cyclins, oncogenes
and components of the DNA repair machinery. In particular, proteases that cleave
ubiquitin chains, referred to as deubiquitylating enzymes (DUBs), have attracted recent
attention due to their accessibility to modulation by small molecules. In this review, we
describe recent evidence of the critical role of DUBs in aspects of cell cycle checkpoint
control, associated DNA repair mechanisms and regulation of transcription, representing
pathways altered in cancer. Therefore, DUBs involved in these processes emerge as
potentially critical targets for the treatment of not only hematological, but potentially also
solid tumors.
Keywords: ubiquitin, deubiquitylating enzyme, transcription, epigenetics, DNA damage response, small molecule
inhibitors, multiple myeloma, cell cycle checkpoints
INTRODUCTION
Posttranslational modifications dictate the fate and function of most proteins. Chemical
modifications by phosphate groups and ubiquitin, a small 76 amino acid protein, are amongst the
most common ones. Targeting enzymes that modulate protein phosphorylation, such as protein
kinases, has been proven to be a suitable inroad to novel anti-cancer therapeutics. In the case of
the ubiquitin system, drug development efforts have been lagging behind due to the complexity
of the ubiquitin conjugating and deconjugating mechanisms, and because many aspects of the
fundamental biology of this pathway, in particular the topology of poly ubiquitin chains and
post-translational modifications present on ubiquitin itself, are not yet fully understood (Cohen
and Tcherpakov, 2010; Swatek and Komander, 2016). Despite this, the clinical approval of the
proteasome inhibitors Bortezomib, Carfilzomib, and Ixazomib has boosted new drug discovery
programs targeting different components of the ubiquitin system (Adams, 2002; Cohen and
Tcherpakov, 2010; Ernst et al., 2013; Herndon et al., 2013; Shirley, 2016).
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The ubiquitin system is involved in the regulation of almost
every cellular activity through proteolytic and non-proteolytic
events, including protein degradation by the 26S proteasome
or through the lysosomal pathway and autophagy, protein–
protein interactions, protein activity and protein localization
(Herndon et al., 2013; Swatek and Komander, 2016). The covalent
attachment of ubiquitin to a target protein is catalyzed by the
sequential action of three enzymes: E1 activating enzyme, E2
conjugating enzyme and E3 ligase. In the final ubiquitylation
step, Ub is usually transferred to an ε-NH2 of a lysine residue
in the target protein. The addition of one or more ubiquitin
monomers to another substrate-attached ubiquitin is possible
and leads to formation of polymeric chains. There are different
types of Ub polymers depending on the linkage and on the
topology of the chain. The process is reversible and the removal of
ubiquitin is catalyzed by a subclass of isopeptidases referred to as
deubiquitylating enzymes or DUBs (Hershko and Ciechanover,
1998; Komander and Rape, 2012; Mevissen et al., 2013; Swatek
and Komander, 2016).
DEUBIQUITYLATING ENZYMES
There are ∼90 DUBs encoded in the human genome, which
are sub classified into seven different families: ubiquitin-specific
proteases (USPs), ubiquitin carboxy-terminal hydrolases
(UCHs), ovarian tumor domain con-taining proteases (OTUs),
Machado-Joseph disease protein domain proteases (MJD),
JAMM/MPN domain-associated metallopeptidases (JAMMs),
the monocyte chemo-tactic protein-induced protein (MCPIP)
and the motif interacting with Ub-containing novel DUB
family (MINDY). Apart from the JAMMs family which has zinc
metalloprotease activity, DUBs are cysteine proteases (Komander
et al., 2009; Fraile et al., 2012; Kolattukudy and Niu, 2012; Abdul
Rehman et al., 2016).
DUB hydrolase activity (predominantly IsoT/USP5) is
required to generate free ubiquitin from its precursors because
Ub is transcribed as a fusion of multiple Ub molecules or as
a fusion with other proteins (Hadari et al., 1992). Keeping
a steady-state level of free Ub is essential for cell viability
(Wang C.H. et al., 2014). Therefore, a second process involving
DUBs is the recycling of ubiquitin by preventing its degradation,
which is mediated by proteasome associated DUBs USP14,
UCH-L5/UCH37, and POH1, or receptor mediated endocytosis
and lysosomal degradation associated DUBs USP8 and AMSH
(Reyes-Turcu et al., 2009; Lee et al., 2011). More specifically,
DUBs antagonize the action of ubiquitin E3 ligases that target
protein substrates for degradation or by regulating E3 ligases
activity and/or stability. Generally, the addition of Ub monomers
or polymers to a protein can also generate non-proteolytic
signals. Thus, DUBs can modulate the outcome of those
signals by two main mechanisms: by removing ubiquitin
polymers or monomers from proteins involved in these signaling
events, but also by editing the linkage and topology of the
ubiquitin chains present in the substrate (Komander et al.,
2009; Bennett, 2010; Fraile et al., 2012; Komander and Rape,
2012).
Deubiquitylating enzymes activity can be tightly regulated
by different means, including transcriptional changes in their
gene expressions, microRNAs, post-translational modifications
including phosphorylation and auto-ubiquitylation, protein
interactions and by changing their subcellular localization
(Komander et al., 2009; Fraile et al., 2012; Yang et al., 2012;
Wijnhoven et al., 2015). Despite that the number of encoded
DUBs is moderate, it is anticipated that most of them act on
a discrete set of protein substrates due to restrictions in Ub
chain linkage recognition as observed for OTUs (Mevissen et al.,
2013) or metalloprotease DUBs (Komander et al., 2009), or the
requirement of interactions with specific adaptors or scaffold
proteins, as noted for JAMMs and a subset of USPs (Ventii and
Wilkinson, 2008; Komander et al., 2009; Rahighi et al., 2009;
Reyes-Turcu et al., 2009; Bremm et al., 2010; Mevissen et al.,
2013).
As we will highlight in this review, DUBs emerge as regulators
of many cellular signaling pathways critical for cell survival,
proliferation, genome stability, and transcriptional control, all of
which are important processes that when altered can contribute
to the development of neoplasia and tumorigenesis. In particular,
ubiquitylation events linked to chromatin-dependent processes
appear to involve a large subset of E3 ligases and DUBs that are
recognized to be prominent targets in cancer. The possibility of
using small molecule inhibitors against DUBs as inroads for anti-
cancer strategies are now receiving a prominent focus in pharma
and academia (Nicholson et al., 2007; Sgorbissa et al., 2010; Shi
and Grossman, 2010; Edelmann et al., 2011; Fraile et al., 2012;
Lim and Baek, 2013; McClurg and Robson, 2015; Lim et al., 2016).
DUBs AFFECTING CHROMATIN
FUNCTION
Histone and other chromatin-associated protein modifications,
together with DNA methylation, provide the cell with long-term
epigenetic gene transcription regulations without affecting its
DNA sequence. Deregulation of these processes is a common
event in cancer development and progression (Esteller, 2007;
Gronbaek et al., 2007; Segal and Widom, 2009; Simo-Riudalbas
and Esteller, 2015). Most histones are post-translationally
modified by the addition of different molecules including
acetylation, methylation, phosphorylation, SUMOylation, and
ubiquitylation. All these histone PTMs (post-translational
modifications) play an important role in gene transcription
regulation and chromatin remodeling, but also in the DNA
damage response (DDR; Weake and Workman, 2008; Zhou
et al., 2009; Zhang T. et al., 2015). Consequences of histone
ubiquitylation have been extensively reviewed (Weake and
Workman, 2008; Belle and Nijnik, 2014). Up to 10% of cellular
histone H2A is mono-ubiquitylated on lysine 119 (H2AK119Ub),
and this modification is crucial for the regulation of transcription,
cell cycle progression, and DDRs (Clague et al., 2015). Poly-
ubiquitylation of the same histone H2A (and its variant H2AX)
on K13/15 is important for the DDR. In the case of Histone
H2B, H2BK120Ub has been identified as a marker of gene
activation. Other histones are also ubiquitylated, such as histone
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H3, which has an important role in nucleosome assembly.
These histone modifications seem to be non-redundant, and
whereas ubiquitylation of histone H2B is related to transcription
activation and silencing, ubiquitylated H2A accumulates at
repressed promoters. Not surprisingly, a number of DUBs
have been identified as histone modifiers (listed in Table 1).
Some of these DUBs present specificity for H2A, others are
specific for H2B, but many of them present dual specificity
toward these two histones (see Table 1). The high number
of DUBs targeting histones suggests redundant or context-
specific roles for these enzymes (Nakagawa et al., 2008; Feng
et al., 2010; Cao and Yan, 2012; Lee et al., 2013; Mosbech
et al., 2013; Zhang et al., 2013). The regulation of histones by
DUBs has already been linked to cancer. Two good examples
are USP22 and BAP1. USP22 deubiquitylates both, H2A and
H2B (Zhang et al., 2008a,b; Atanassov et al., 2009; Wang and
Dent, 2014). In a recent clinicopathological study in colon
carcinoma samples, ubiquitylation of H2B (uH2B) was found
to be decreased in colon cancers as compared to normal colon
epithelium. Interestingly, high expression levels of USP22 in
these tumor samples statistically correlated with reduced levels
of uH2B (Wang Z. et al., 2015). USP22 has been linked to
poor prognosis in cancer, making it a very attractive target in
cancer research. Overexpression of this DUB has been found
in colorectal cancer (Liu Y.L. et al., 2011), gastric cancer (Yang
et al., 2011; He et al., 2015), liver cancer (Tang et al., 2015a,b),
breast cancer (Zhang Y. et al., 2011), glioma (Liang J. et al.,
2014), pancreatic cancer (He et al., 2015), non-small-cell lung
cancer (Hu et al., 2012), salivary adenoid cystic carcinoma
(Dai et al., 2014), human pharyngeal squamous cell carcinoma
(Dou et al., 2014), and oral squamous cell carcinoma (Piao
et al., 2012). BAP1 is a nuclear DUB that targets histone 2A
mono-ubiquitylation on lysine 119 (H2AK119ub1; as part of the
Polycomb repressor unit; Scheuermann et al., 2010) and regulates
histone H3 lysine methylation and chromatin functions (Dey
et al., 2012). The forkhead transcription factor FOXK2 acts a
scaffold protein between BAP1 and DNA, promoting targeted
epigenetic regulation by BAP1 (Ji et al., 2014; Okino et al., 2015).
BAP1 has been identified as a tumor suppressor and as a potential
prognostic marker for a number of cancer types. Both, germline
and somatic mutations and nuclear expression loss of BAP1
have been linked to increased susceptibility and poor prognosis
in malignant melanocytic proliferations (Wiesner et al., 2011;
Piris et al., 2015), mesothelioma (Bott et al., 2011), basal cell
carcinoma (Mochel et al., 2015), meningioma (Abdel-Rahman
et al., 2011), lung cancer (Abdel-Rahman et al., 2011), bladder
cancer (Nickerson et al., 2014), thymic carcinoma (Wang Y. et al.,
2014), and clear cell renal cell carcinoma (Murali et al., 2013).
Although the majority of the published studies suggest that the
effects of BAP1 in cancer involve a disruption of the epigenetic
homeostasis in these tumors (Wang Y. et al., 2014), for some
researchers, it is not so clear that the antitumor effect of BAP1
is only dependent on H2A deubiquitylation (Pena-Llopis et al.,
2012).
DUBs ROLE IN THE CROSSTALK
BETWEEN THE DIFFERENT HISTONE
PTMs
The crosstalk between different histone PTMs has been described
(Zhang T. et al., 2015). JAMM/MPN, a member of the domain-
associated metallopeptidases, plays an important role in gene
expression regulation by coordinating acetylation of histones
with deubiquitylation of histone H2A and regulating by this
way the association of histone H1 with nucleosomes (Zhu et al.,
2007). USP22 has been found to be associated with the Spt-Ada-
Gcn5-acetyltransferase (SAGA) histone acetyltransferase (HAT)
complex. In this context, USP22 deubiquitylates histone H2B
and other components of the shelterin complex (Atanassov
TABLE 1 | Selection of deubiquitylating enzymes (DUBs) involved in modulating histone H2A/B ubiquitylation.
DUB Histone (substrate) Process Selected reference
USP3 H2A, γH2AX and H2B Cell cycle and DNA double-strand break response Nicassio et al., 2007
USP7 H2A and H2B Gene expression van der Knaap et al., 2005; Luo et al., 2015
USP10 H2A (H2A.Z) Transcriptional activation Draker et al., 2011
USP12 H2A and H2B Xenopus development Joo et al., 2011
USP16 H2A Cell cycle and gene expression Joo et al., 2007; Gu et al., 2016
USP21 H2A Transcriptional activation Nakagawa et al., 2008
USP22 H2A and H2B Embryonic development and telomere integrity Zhang et al., 2008a,b; Atanassov et al., 2009;
Wang and Dent, 2014
USP29 H2A and H2B DNA double-strand break response Mosbech et al., 2013
USP36 H2B Unknown Taillebourg et al., 2012
USP44 H2A and H2B DNA double-strand break response (H2A) and stem cell differentiation (H2B) Fuchs et al., 2012; Mosbech et al., 2013
USP46 H2A and H2B Xenopus development Joo et al., 2011
USP49 H2B Co-transcriptional pre-mRNA processing Zhang et al., 2013
BAP1 H2A Gene expression Scheuermann et al., 2010
OTUB1 Histones (unspecified) DNA double-strand break response Sato et al., 2012
BRCC36 H2A and γH2AX DNA double-strand break response Shao et al., 2009
MYSM1 H2A Gene expression Zhu et al., 2007; Jiang et al., 2015; Li et al., 2016
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et al., 2009). USP17 regulates histone acetylation through
deubiquitylation of K63-polyubiquitylated SDS3, inhibiting the
histone deacetylase activity (HDAC) of SDS3 and subsequently
the proliferation and anchorage-independent growth of tumor
cells (Ramakrishna et al., 2011, 2012). A recent study describes
that USP7 interacts with and deubiquitylates Tip60, an
acetyltransferase targeting histones, resulting in its stabilization
(Dar et al., 2013). As mentioned above, BAP1 forms together
with ASXL1 the PR-DUB complex that removes ubiquitin from
H2AK119Ub. In a recent study, LaFave et al. (2015) found that
BAP1 deletion in mice increased the levels of tri-methylated
histone H3 (H3K27me3) and reduced mono-methylation of
the histone H4 (H4K20me1). A member of the OTU family
of DUBs called TRABID (also ZRANB1) was found to be an
innate immunological regulator of inflammatory T cell responses.
TRABID regulates histone methylation (H3K9me2, H3K9me3,
and H3K4me3) at the promoter of IL-12 by deubiquitylating and
stabilizing the histone demethylase JMJD2D (Jin et al., 2016). In
the same study, ectopic expression of TRABID reduced K29, and
to a lesser extent K11 ubiquitylation of JMJD2D. This data is
consistent with previous published studies describing specificity
of this DUB toward K29-linked ubiquitin chains in in vitro assays
(Virdee et al., 2010; Licchesi et al., 2012). The protein TIP5 is part
of the nucleolar remodeling complex (NoRC) that modulates the
silencing of a fraction of rDNA by recruiting histone and DNA
methyltransferases. TIP5 is deubiquitylated and stabilized by
USP21, resulting in an increase of H3K4me3 and rDNA promoter
methylation (Khan et al., 2015). It had been previously described
that H2A ubiquitylation controls the di- and tri-methylation of
H3K4. In the same study, the authors describe the indirect effects
of USP21 on H3K4m2, and H3K4m3 modifications through its
H2A histone deubiquitylating activity (Nakagawa et al., 2008). An
interesting study has recently linked the roles of the DUB USP7
on epigenetic regulation, cell cycle, and DNA repair (Wang Q.
et al., 2016). Upon DNA damage, USP7 interacts, deubiquitylates
and stabilizes the histone demethylase PHF8, inducing the
specific expression of a subset of genes, including the cell cycle
regulator cyclin A2. In the same article, USP7, PHF8, and
cyclin A2 were found to be overexpressed in breast carcinomas,
correlating with the histological grade of disease. USP24 was also
found to target histones by controlling the levels of the histone-
lysine N-methyltransferase Suv39h1, resulting in a modulation
of the H3K9me levels. Single-nucleotide polymorphisms (SNPs)
of USP24 were found in lung cancer. The variants 930C/T
and 7656T/C were increased in tumor samples and were found
to induce USP24 expression by stabilizing RNA. (Wang Y.C.
et al., 2015). LSD1 (lysine-specific demethylase 1) removes methyl
groups from H3K4 and also from H3K9. LSD1 has been found to
be upregulated in many tumors and its protein levels regulated
by the ubiquitin proteasome system. Using a library of siRNA
against all human DUBs, USP28 was found as the DUB involved
in the stabilization of LSD1. USP28 interacts and deubiquitylates
LSD1, and the expression levels of the two proteins correlate
well in tumor cell lines and tumor samples (Wu et al., 2013).
In conclusion, all these examples are starting to point toward an
emerging and important role of the DUBs in the regulation of
gene expression by epigenetic events in cancer.
DUBs and DNA METHYLATION
Only one DUB, USP7, has been described to have a role in
the DNA methylation process. USP7 regulates the inheritance
of DNA methylation patterns through control of the abundance
of Dnmt1, the DNA methyltransferase responsible for this
epigenetic mark (Bronner, 2011; Qin et al., 2011). USP7 is part
of a protein complex with Dnmt1, the histone acetyl transferase
Tip60 and the ubiquitin ligase Uhrf1. USP7 and Urf1 tightly
regulate the abundance of Dnmt1 in order to control DNA
methylation inheritance and replication of methylation patterns.
Supporting the role of ubiquitylation in the maintenance of
DNA methylation, Nishiyama et al. (2013) have discovered that
the ubiquitylation of histone H3 is necessary to keep the DNA
methylation mark by Dnmt1.
DUBs and DNA DAMAGE
In order to achieve the mutational status that leads to malignancy,
tumor cells often deregulate the DDR and the genome
maintenance systems (Hanahan and Weinberg, 2011). Under
normal physiological conditions, cells have sensor proteins that
check for damage in their genome, and once these proteins
detect the lesion, repair enzymes are recruited to the damage site
to promote repair. Small lesions are repaired by base excision
repair (BER), nucleotide excision repair (NER), mismatch repair
(MMR) and the Fanconi anemia (FA) pathways. More harmful
damages such as double-stranded breaks (DSBs) can be repaired
by non-homologous end joining (NHEJ) or through homologous
recombination (HR). All the DDR pathways are tightly regulated
by PTMs, which includes ubiquitylation/deubiquitylation events.
Therefore, DUBs are involved in multiple DDR checkpoints in
addition to their capability to modulate histone modifications
(Table 2 and Figure 1; Bennett and Harper, 2008; Jacq et al.,
2013; Liu et al., 2016; Nie and Boddy, 2016). FA complementation
group D2 protein (FANCD2) and proliferating cell nuclear
(PCNA), when mono-ubiquitylated, induce the DDR. USP1
targets FANCD2, FANC1, and PCNA for deubiquitylation.
FANCD2 and FANC1 are implicated in the FA pathway and
PCNA in the translesion synthesis process (Nijman et al., 2005;
Oestergaard et al., 2007; Hendel et al., 2011; Villamil et al.,
2013; Kim and Kim, 2016). USP1 mutations and deregulated
expression levels have been reported in different tumors (Garcia-
Santisteban et al., 2013). The Chk2-p53-PUMA pathway is
another regulator of the DDR generated by double-strand
breaks. USP28 was found to stabilize two components of this
pathway upon DNA damage, Chk2 and 53BP1 (Zhang et al.,
2006). The proteasome-associated DUB Rpn11/POH1 has been
described as an important regulator of ubiquitin conjugates
generated after DNA damage, thereby representing an important
component of the double-strand break response (Butler et al.,
2012). BRIT1 is an early DDR factor that is recruited upon DSBs
by phosphorylated H2AX histone (γ-H2AX), and it contributes
to the final repair process by inducing chromatin relaxation.
BRIT1 is deubiquitylated and stabilized by USP8 with the help
of the scaffold protein BRUCE, tightly regulating the action
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TABLE 2 | Deubiquitylating enzymes associated with DNA damage responses (DDR).
DUB Non-histone substrate DDR pathway Selected reference
USP1 FANCD2, FANCI and PCNA Fanconi anemia, post-replication repair (PRR) and
translesion DNA synthesis (TLS)
Nijman et al., 2005; Oestergaard et al., 2007; Hendel et al.,
2011; Villamil et al., 2013; Kim and Kim, 2016
USP2a Mdm2 p53 Stevenson et al., 2007
USP4 Auto-deubiquitylation and ARF-BP1 DSB-response (HR), p53 Zhang X. et al., 2011; Wijnhoven et al., 2015
USP5 p53 p53 Dayal et al., 2009
USP7 Mdm2, p53, Claspin, Chk1,
Ring1b, Bmi1 and RNF168
p53, ATR-Chk1 and γ-H2AX (DSBs and SSBs) Brooks et al., 2007; Faustrup et al., 2009; Brooks and Gu,
2011; Alonso-de Vega et al., 2014; Qian et al., 2015; Zhu
et al., 2015
USP8 BRIT1 BRIT1–SWI–SNF DSB-response Ge et al., 2015
USP9X Claspin ATR-Chk1 McGarry et al., 2016
USP10 p53 and MSH2 ATM-p53 and mismatch repair (MMR) Yuan et al., 2010; Zhang et al., 2016
USP11 p53 DDR to etoposide Ke et al., 2014
USP20 Claspin ATR-Chk1 Yuan et al., 2014; Zhu et al., 2014
USP24 p53 and DDB2 p53-PUMA Zhang L. et al., 2012, 2015
USP28 Chk2 and 53BP1 Chk2-p53-PUMA Zhang et al., 2006
USP29 p53 and Claspin p53 and ATR-Chk1 Liu et al., 2011a; Martin et al., 2015
UCH-L5 NFRKB DSB-response (HR) Nishi et al., 2014
OTUB1 p53 p53 Sun et al., 2012
OTUD5 p53 and PDCD5 p53 Luo et al., 2013; Park et al., 2015
Rpn11 Ubiquitin conjugates generated by
DNA damage
DNA double-strand break response Butler et al., 2012
of BRIT1 at damaged sites (Ge et al., 2015). USP4 has been
found to be important for DSB repair by promoting homologous
recombination. USP4 is auto-deubiquitylated on lysine, but
potentially also on cysteine residues, and its deubiquitylation is an
important step to permit interaction with the DNA-end resection
factor CtIP and MRE11-RAD50-NBS1 (MRN) complex, thereby
recruiting CtIP to the damaged sites (Wijnhoven et al., 2015).
USP10 was recently identified as a partner of MSH2 by mass
spectrometry-based interactome studies. MSH2 is an important
factor for the mismatch repair pathway and for the resistance to
DNA-damaging agents. USP10 stabilizes MSH2, and knockdown
of USP10 in lung cancer cells reduces the sensitivity of these
cells to DNA damaging agents. A well-known mechanism of
DDR involves histone H2AX, which is phosphorylated and
accumulated at damaged sites. Then, the ubiquitin ligases
RNF168 and RNF8 ubiquitylate γ-H2AX, thereby inducing the
accumulation of repair factors. USP7 has been identified as a
regulator of γ-H2AX and H2A ubiquitylation by modulating the
stability of the E3 ubiquitin ligases RNF168, RINGB1, and BMI1
(Zhu et al., 2015). USP7 is a regulator of different pathways of the
DDR, and it is also a modulator of the ATR-Chk1 pathway since
it controls the levels of two main components of this response,
Chk1 (an essential checkpoint kinase in the DDR) and Claspin
(an important component of the ATR-Chk1 axis) (Faustrup et al.,
2009; Alonso-de Vega et al., 2014). Other DUBs have also been
identified to stabilize Claspin and, therefore, to modulate the
ATR-Chk1 pathway, such as is the case for USP9X (McGarry
et al., 2016), USP29 (Martin et al., 2015), and USP20 (Yuan
et al., 2014; Zhu et al., 2014). In an interesting study, Nishi et al.,
identified UCH-L5 as the only DUB from a library of 90 DUBs
that were able to promote changes in the DDR during three
different assays: recruitment at the damaged sites, DDR signaling
modulation and DSB repair. The authors found that UCH-L5
interacted with and stabilized NFRKB. NFRKB is a component of
the INO80 complex that promotes HR and DNA-end resection
(Nishi et al., 2014).
REGULATION OF p53, c-MYC AND
OTHER ONCOGENES BY DUBs
The tumor suppressor p53 is a transcription factor able to control
important cellular pathways including DDR, cell cycle, apoptosis,
angiogenesis, and senescence. It is called “the guardian of the
genome” because of its ability to prevent genome mutation and
tumor onset and progression (Nag et al., 2013). p53 levels and
subcellular localization are mainly regulated by ubiquitylation
(Brooks and Gu, 2011). A number of DUBs can modulate p53
signals: USP7 deubiquitylates both p53 and MDM2, one of the
ubiquitin ligases that ubiquitylates p53, thereby stabilizing both
proteins (Brooks et al., 2007; Brooks and Gu, 2011). Upon
DNA damage, USP10 deubiquitylates and activates p53. The
same study shows that USP10 suppresses tumor cell growth
in cells expressing wild-type p53 (Yuan et al., 2010). USP2a
associates with and deubiquitylates MDM2, but not p53, and
promotes MDM2-dependent p53 degradation (Stevenson et al.,
2007). Overexpression of this DUB was found in different tumors
such as glioma (Boustani et al., 2016), bladder cancer (Jeong
et al., 2015), prostate cancer (Nelson et al., 2012), and oral
squamous carcinoma (da Silva et al., 2009). USP4 interacts with
and deubiquitylates another E3 ubiquitin ligase for p53, ARF-
BP1/Mule/HUWE, leading to the stabilization of ARF-BP1 and
subsequent reduction of p53 levels. The same authors found that
Frontiers in Genetics | www.frontiersin.org 5 July 2016 | Volume 7 | Article 133
fgene-07-00133 July 27, 2016 Time: 16:14 # 6
Pinto-Fernandez and Kessler DUBs As Mainstream Cancer Targets
FIGURE 1 | Deubiquitylating enzymes (DUBs) emerge as major pharmacological targets. Uncontrolled cell proliferation is one of the hallmarks of cancer.
Recent literature evidence establishes the critical role of DUBs in aspects of cell cycle checkpoint control, associated DNA repair mechanisms and regulation of
transcription, representing pathways altered in cancer. Therefore, DUBs involved in these processes emerge as potentially critical targets for the treatment of not only
hematological, but potentially also solid tumors. Small molecule inhibitors available for a subset of DUBs are indicated in red.
USP4 is overexpressed in several types of human cancer, and
they suggest that USP4 could be a potential oncogene (Zhang
X. et al., 2011; Xing et al., 2016). In response to oxidative
stress, USP29 binds to and stabilizes p53. Accumulated p53
quickly induces apoptosis under these conditions (Liu et al.,
2011a). OTUB1 is a DUB with preference for substrates with
poly ubiquitin K48 linked chains (Mevissen et al., 2013; Altun
et al., 2015) that was reported to suppress MDM2-mediated p53
ubiquitylation (Sun et al., 2012). Interestingly, the mechanism
by which OTUB1 controls p53 ubiquitylation is independent of
its DUB activity. OTUB1 blocks p53 ubiquitylation by MDM2
by interacting with and inhibiting UbcH5, and E2 conjugating
enzyme for MDM2. Overexpression of OTUB1 in cells drastically
stabilizes and activates p53, leading to apoptosis and to a marked
inhibition of cell proliferation in a p53-dependent manner (Sun
et al., 2012). OTUB1 is also involved in the inhibition of another
E2 enzyme, UBC13 (Sato et al., 2012). Since UBC13 is the
only E2 involved in the conjugation of K63 Ub chains, this
makes OTUB1 an interesting regulator of both, K63 and K48
polyubiquitin chains signals. OTUB1 is also an activator of a
very important oncogene in cancer, RAS. Remarkably, OTUB1
deubiquitylates mono- and di-ubiquitylated RAS, independently
of its activation status, resulting in the translocation of the RAS
protein to the plasma membrane where it is normally activated
(Baietti et al., 2016). OTUB1 expression levels are related with
poor prognosis and metastasis in colorectal cancer (Zhou et al.,
2014), ovarian cancer (Wang Y. et al., 2016), non-small-cell
lung carcinomas (Baietti et al., 2016), and it has been linked
to resistance to chemotherapy in breast cancer bearing patients
(Karunarathna et al., 2016) and prostate cancer cell invasion
(Iglesias-Gato et al., 2015). Knock-down of USP5, the only
DUB with specificity for unanchored poly ubiquitin, stabilizes
p53 as well. The authors propose a model in which p53 is
selectively stabilized because the unanchored poly ubiquitin that
accumulates after USP5 knockdown is able to compete with
ubiquitylated p53 for proteasomal proteolysis (Dayal et al., 2009).
Another DUB, OTUD5, interacts and deubiquitylates p53 in
response to DNA damage stress (Luo et al., 2013). PDCD5 is an
additional factor accumulated upon DNA damage and regulates
the p53 pathway. In a two yeast two-hybrid study to identify
partners of PDCD5 in the presence of genotoxic stress, OTUD5
was found to interact with and stabilize PDCD, thereby unveiling
a dual role for this enzyme in the regulation of the p53 signals
(Park et al., 2015). In another two-hybrid study, USP24 was
found to interact with and stabilize DDB2 (UV damage binding
protein; Zhang L. et al., 2012). Posteriori, the same authors
identified an upregulation of USP24 in a number of tumor cell
lines. They found also that USP24 deubiquitylates p53, activating
the PUMA pathway, a regulator of DNA-damage-induced
apoptosis (Zhang L. et al., 2015). Similarly, it was found that
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USP11 deubiquitylates p53 in response to genotoxicity induced
by etoposide (Ke et al., 2014). Other DUBs are linked to
the turn-over of important tumor suppressors and oncogenes.
For instance, oncogenic transformation by the stabilization of
the dual specificity (Tyr/Thr) phosphatase Cdc25A appears
to be controlled by Dub3/USP17 (Pereg et al., 2010). USP17
knockdown does lead to a cell cycle arrest in G1/S and G2/M,
and high levels of USP17 have been observed in lung, colon,
esophagus, and cervix tumor biopsies, underpinning its role in
cell cycle control (McFarlane et al., 2010). USP7 is abundantly
expressed in many cell types and, as mentioned above, it
was shown to deubiquitylate MDM2, thereby modulating p53
stability, but it also has other cellular substrates including
FOXO4, Claspin and FOXO3 (Nicholson and Suresh Kumar,
2011). Knockdown of USP7 leads to cell cycle arrest in G1
or G2 (Khoronenkova et al., 2012), which is underpinning its
role in controlling several aspects of cell division. The JAMM-
domain containing DUB BRCC36 stimulates activity of BRCA1,
leading to G2/M checkpoint arrest/control (Mallery et al., 2002).
In addition to its role in the p53 pathway, USP28 was also shown
to stabilize the oncogene c-MYC after DNA damage. The same
authors and others found high expression levels of this DUB
in colon, lung, glioma, bladder, and breast carcinomas (Popov
et al., 2007a,b; Diefenbacher et al., 2014, 2015; Guo et al., 2014;
Wang Z. et al., 2016). USP36 and USP37 also control the stability
of c-Myc and thereby affect c-Myc oncogene driven cellular
proliferation (Zhang et al., 2006; Pan et al., 2015; Sun et al.,
2015).
DUBs AFFECTING CELL CYCLE
REGULATORS
The accumulation and turnover of proteins that regulate the cell
cycle such as cyclins, CDKs, and checkpoint signaling molecules
is highly orchestrated and controlled to ensure the timely
progression through the cell cycle. Inappropriate expression
of one or more of these proteins is a common feature of
virtually all human tumors. A large number of studies have
underscored the importance of E3 ubiquitin ligases and the
role they play in regulating cell cycle components [reviewed
in Li and Jin (2012)]. However, DUBs that counterbalance E3
ligase activity may also be critical in cell cycle progression (Song
and Rape, 2008; Fraile et al., 2012). Indeed, DUB function
is frequently miss- regulated in cancer, and our knowledge
concerning DUB expression and activity during the different
phases of the cell cycle is expanding (for a specific review, see
Lim et al., 2016). The regulation of chromatin structure and
transcription is one of the key mechanisms by which DUBs exert
cell cycle control. DUBs involved in DNA damage checkpoints
are exerting effects on cell cycle progression, and these include
USP1, USP3, USP7, USP10, USP11, USP16, USP21, USP22,
USP28, BRCC36, MYSM1, and BAP1 (Jacq et al., 2013; see
also section above). Another key cell cycle checkpoint is the
one controlling the correct mitotic spindle assembly, and DUBs
such as USP44, CYLD, and USP15 were reported to modulate
this process. USP44 acts as a tumor suppressor by preventing
chromosome segregation errors (Holland and Cleveland, 2012)
via deubiquitylation of the anaphase promoting complex (APC)
coactivator Cdc20 (Stegmeier et al., 2007a), and USP44 deletion
leads to spontaneous tumor formation, preferentially in the
lungs (Zhang Y. et al., 2012). USP15 stabilizes newly synthesized
REST and rescues its expression at mitotic exit (Faronato et al.,
2013). CYLD targets Plk1 and contributes to regulating mitotic
entry (Stegmeier et al., 2007b). USP3 modifies chromatin and is
required for S-phase progression (Nicassio et al., 2007). USP2a,
as mentioned above, has been linked to different types of cancer.
In bladder cancer cells, USP2a was found to deubiquitylate
and to stabilize the cell cycle regulator, Cyclin A1, controlling
proliferation of these cells (Kim et al., 2012). Taken together,
∼15 (out of ∼90) DUBs have been directly linked to molecular
processes of the cell cycle (Figure 1).
WILL DUB INHIBITION WORK IN
CANCER?
Generally, DUB function is linked to most cellular processes,
but in particular appears to cluster around three major pathways
that are commonly deregulated in tumorigenesis. These include
transcriptional and epigenetic control of gene expression,
DDR pathways and cell cycle checkpoint control (Figure 1).
These processes are functionally interconnected, for instance
DNA repair mechanisms that are part of cell cycle control
checkpoints in the transitions from G2 to S and M to cytokinesis.
The associated subset of DUBs are therefore attractive drug
candidates, although so far small molecule inhibitors for only
a few of them have been reported many of them are subject
to intense screening activities (for a comprehensive review,
see Kemp, 2016) including natural compounds (Tsukamoto,
2016). The most relevant DUBs related to these pathways with
existing chemical matter are UCH-L1, USP1, USP7, USP9,
USP14, and UCH-37. Inhibitors of the USP1/UAF complex
have been reported, such as ML323, developed based on a
N-Benzyl-2-phenylpyrimidin scaffold (Liang Q. et al., 2014),
and C527 (SJB3-019A; Mistry et al., 2013). Interestingly,
ML323 was found to sensitize the non-small lung cancer cell
line H596 to cisplatin (Liang Q. et al., 2014). Most efforts
so far have been focused on USP7 (HAUSP), because of its
effect on the MDM2-p53 axis. Reported inhibitors include
Hybrigenix HBX41108/HBX19818, all based on quinazoline core
structures (Colland et al., 2009; Reverdy et al., 2012), Progenra
P22077/P5091 developed from a phenyl-thio-2-thienyl building
block (Altun et al., 2011; Chauhan et al., 2012), but also natural
compounds such as spongiacidin (Yamaguchi et al., 2013).
Most promisingly, the USP7 inhibitor P5091 was shown to be
able to overcome Bortezomib resistance in Multiple Myeloma
cells (Chauhan et al., 2012). However, this chemical scaffold
has limited pharmacodynamics properties. A different small
molecule, WP1130 and its improved derivative EOAI3402143
based on second-generation tyrphostin derivatives [initially
identified as Janus-activated kinase (JAK)-signal transducer],
appear to inhibit USP9X and USP24 and consequently
increased Myeloma tumor cell apoptosis in vitro and in vivo
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(Peterson et al., 2015). USP9X affects chromosome alignment and
segregation via ubiquitylation of survivin (Vong et al., 2005), but
has potentially other roles including cell sensitization by affecting
the stability of MCL-1, BCR-ABL, and ITCH (Schwickart et al.,
2010; Kushwaha et al., 2015). Spautin-1, a quinazolinamine
derivative, was characterized as a USP10 inhibitor that to some
extent also targets USP13 (Liu et al., 2011b). The resemblance
of the quinazoline chemical core element to USP7 inhibitors
may offer an opportunity to use this scaffold to further develop
inhibitors specific for other USPs.
CLINICAL PERSPECTIVE FOR DUB
INHIBITORS
The USP14 inhibitor IU1 and dual inhibitors of USP14/UCHL5
(proteasomal DUBs) such as b-AP15 (D’Arcy et al., 2011),
a bis[(4-nitrophenyl)methylene]-piperidinone derivative or its
more recently developed analog VLX1570 (Wang X. et al., 2015),
show potentially promising effects that could be potentially
translated into the clinic. IU1 appears to accelerate degradation of
protein aggregates (Lee et al., 2010), and b-AP15 also overcomes
Bortezomib resistance in Multiple Myeloma cells (Tian et al.,
2014). As a consequence, VLX1570 has now been cleared to enter
Phase I/II for the treatment against Multiple Myeloma patients
for whom every other drug combination failed (Taylor, 2016).
This represents the first DUB inhibitor reaching the clinical
phase, and it is expected that within the next one to two years,
a number of other DUB inhibitor candidates will follow also
for the potential treatment of solid tumors. For instance, p53
wildtype expressing tumors (e.g., certain colon cancers) may be
suitable for USP7/10 inhibitor based treatment strategies. c-Myc-
dependent tumors (adenocarcinomas and non-small lung, breast,
and colon cancer) could potentially respond to USP28, USP36,
USP37, all DUBs affecting c-Myc protein turnover. One third
of human cancers present mutations in the oncogene RAS or
in components of its effector pathways (Matallanas and Crespo,
2010). The recent discovery describing how OTUB1 control RAS
activity (Baietti et al., 2016) may lead to the development of
OTUB1 inhibitors targeting RAS mutation based cancers such
as pancreatic cancer, colon and melanoma. Clearly, DUBs have
now reached center stage as cancer targets, and novel inhibitors
for this enzyme class will provide the framework for more
effective single agent or combination therapies to better treat
hematological and solid tumors.
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